Cargando…

An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein

Since the first appearance of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2) in China on December 2019, the world has now witnessed the emergence of the SARS- CoV-2 outbreak. Therefore, due to the high transmissibility rate of virus, there is an urgent need to design and develop v...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghafouri, Fatemeh, Cohan, Reza Ahangari, Noorbakhsh, Farshid, Samimi, Hilda, Haghpanah, Vahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336711/
https://www.ncbi.nlm.nih.gov/pubmed/32702713
http://dx.doi.org/10.21203/rs.3.rs-30374/v1
_version_ 1783554373290295296
author Ghafouri, Fatemeh
Cohan, Reza Ahangari
Noorbakhsh, Farshid
Samimi, Hilda
Haghpanah, Vahid
author_facet Ghafouri, Fatemeh
Cohan, Reza Ahangari
Noorbakhsh, Farshid
Samimi, Hilda
Haghpanah, Vahid
author_sort Ghafouri, Fatemeh
collection PubMed
description Since the first appearance of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2) in China on December 2019, the world has now witnessed the emergence of the SARS- CoV-2 outbreak. Therefore, due to the high transmissibility rate of virus, there is an urgent need to design and develop vaccines against SARS-CoV-2 to prevent more cases affected by the virus. In this study, a computational approach is proposed for vaccine design against the envelope (E) protein of SARS-CoV-2, which contains a conserved sequence feature. First, we sought to gain potential B-cell and T-cell epitopes for vaccine designing against SARS-CoV-2. Second, we attempted to develop a multi-epitope vaccine. Immune targeting of such epitopes could theoretically provide defense against SARS-CoV-2. Finally, we evaluated the affinity of the vaccine to major histocompatibility complex (MHC) molecules to stimulate the immune system response to this vaccine. We also identified a collection of B-cell and T-cell epitopes derived from E proteins that correspond identically to SARS-CoV-2 E proteins. The in-silico design of our potential vaccine against E protein of SARS-CoV-2 demonstrated a high affinity to MHC molecules, and it can be a candidate to make a protection against this pandemic event.
format Online
Article
Text
id pubmed-7336711
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Journal Experts
record_format MEDLINE/PubMed
spelling pubmed-73367112020-07-14 An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein Ghafouri, Fatemeh Cohan, Reza Ahangari Noorbakhsh, Farshid Samimi, Hilda Haghpanah, Vahid Res Sq Article Since the first appearance of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2) in China on December 2019, the world has now witnessed the emergence of the SARS- CoV-2 outbreak. Therefore, due to the high transmissibility rate of virus, there is an urgent need to design and develop vaccines against SARS-CoV-2 to prevent more cases affected by the virus. In this study, a computational approach is proposed for vaccine design against the envelope (E) protein of SARS-CoV-2, which contains a conserved sequence feature. First, we sought to gain potential B-cell and T-cell epitopes for vaccine designing against SARS-CoV-2. Second, we attempted to develop a multi-epitope vaccine. Immune targeting of such epitopes could theoretically provide defense against SARS-CoV-2. Finally, we evaluated the affinity of the vaccine to major histocompatibility complex (MHC) molecules to stimulate the immune system response to this vaccine. We also identified a collection of B-cell and T-cell epitopes derived from E proteins that correspond identically to SARS-CoV-2 E proteins. The in-silico design of our potential vaccine against E protein of SARS-CoV-2 demonstrated a high affinity to MHC molecules, and it can be a candidate to make a protection against this pandemic event. American Journal Experts 2020-05-20 /pmc/articles/PMC7336711/ /pubmed/32702713 http://dx.doi.org/10.21203/rs.3.rs-30374/v1 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Article
Ghafouri, Fatemeh
Cohan, Reza Ahangari
Noorbakhsh, Farshid
Samimi, Hilda
Haghpanah, Vahid
An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein
title An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein
title_full An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein
title_fullStr An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein
title_full_unstemmed An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein
title_short An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein
title_sort in-silico approach to develop of a multi-epitope vaccine candidate against sars-cov-2 envelope (e) protein
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336711/
https://www.ncbi.nlm.nih.gov/pubmed/32702713
http://dx.doi.org/10.21203/rs.3.rs-30374/v1
work_keys_str_mv AT ghafourifatemeh aninsilicoapproachtodevelopofamultiepitopevaccinecandidateagainstsarscov2envelopeeprotein
AT cohanrezaahangari aninsilicoapproachtodevelopofamultiepitopevaccinecandidateagainstsarscov2envelopeeprotein
AT noorbakhshfarshid aninsilicoapproachtodevelopofamultiepitopevaccinecandidateagainstsarscov2envelopeeprotein
AT samimihilda aninsilicoapproachtodevelopofamultiepitopevaccinecandidateagainstsarscov2envelopeeprotein
AT haghpanahvahid aninsilicoapproachtodevelopofamultiepitopevaccinecandidateagainstsarscov2envelopeeprotein
AT ghafourifatemeh insilicoapproachtodevelopofamultiepitopevaccinecandidateagainstsarscov2envelopeeprotein
AT cohanrezaahangari insilicoapproachtodevelopofamultiepitopevaccinecandidateagainstsarscov2envelopeeprotein
AT noorbakhshfarshid insilicoapproachtodevelopofamultiepitopevaccinecandidateagainstsarscov2envelopeeprotein
AT samimihilda insilicoapproachtodevelopofamultiepitopevaccinecandidateagainstsarscov2envelopeeprotein
AT haghpanahvahid insilicoapproachtodevelopofamultiepitopevaccinecandidateagainstsarscov2envelopeeprotein